For instance, aptamers targeting PD-L1 have been utilised to deliver siRNA therapeutics, effectively silencing PD-L1 expression and enhancing antitumour immunity in triple-negative breast cancer cells. This evidence concerns the gene CD274 and triple-negative breast carcinoma.